The tumor's inflammatory response may be the key to stopping resistance
For decades, a KRAS mutation in colorectal cancer meant few good options and a grim prognosis — then came targeted inhibitors that offered hope, only to be outmaneuvered by tumors that learned, with unsettling speed, to survive. Researchers at MD Anderson and Weill Cornell have now mapped the mechanisms of that escape, finding that cancer cells resist not only by mutating further but by changing who they are — shifting behavior, triggering inflammatory alarms, buying time. Their discovery that blocking TBK1 can silence that alarm and restore the drug's power suggests that resistance, long treated as inevitable, may yet be intercepted.
- KRAS mutations drive nearly half of all colorectal cancers, and the drugs designed to target them — adagrasib and sotorasib — lose their effectiveness within months as tumors adapt and escape.
- Researchers found that resistance is not a single event but a dual strategy: some cancer cells acquire new mutations to bypass the drug, while others simply change their behavior without altering their DNA at all.
- When KRAS inhibitors first strike, tumors fire an early inflammatory alarm — activating survival pathways that act as a cellular distress signal, buying the cancer time to reorganize and resist.
- In laboratory models, blocking TBK1 — the protein at the center of that inflammatory cascade — silenced the alarm and made resistant tumors vulnerable to KRAS inhibitors once again.
- The findings, published in Cancer Cell, point toward a combination therapy strategy that targets both the genetic escape routes and the tumor's adaptive inflammatory response simultaneously.
- The work remains preclinical, but it offers patients with KRAS-mutant colorectal cancer a concrete and rational direction forward — one that treats resistance not as a wall, but as a mechanism that can be disrupted.
Nearly half of all colorectal cancers carry mutations in the KRAS gene — a marker of aggressive disease that, for decades, offered patients little hope. When inhibitors like adagrasib and sotorasib arrived, they seemed to change the equation. Some tumors shrank. But the victories were short-lived. Within months, the cancer adapted, and the drugs stopped working.
Researchers at UT MD Anderson Cancer Center and Weill Cornell Medicine set out to understand why. Led by Salvador Alonso Martinez and Kevan Chu, the team collected tumor samples from patients before, during, and after treatment with KRAS inhibitors, using advanced genetic sequencing and single-cell spatial transcriptomics to map what was happening inside individual cancer cells as resistance took hold.
What they found was more complex than a simple mutation story. Some resistant cells had acquired new genetic changes that let them bypass the drug. But others had not mutated at all — they had simply changed their behavior, adopting new survival strategies without rewriting their DNA. Both mechanisms were often at work in the same tumor, simultaneously.
The team also identified something unexpected: the moment KRAS inhibitors hit a tumor, the cancer cells triggered an inflammatory alarm response — activating pathways that functioned like a cellular call for help, buying time while the tumor reorganized its defenses. This early inflammatory surge appeared to be a survival reflex, and it worked.
That observation pointed toward a potential solution. When researchers tested TBK1 blockade — targeting the protein central to that inflammatory cascade — in laboratory organoids grown from resistant tumors, the cancer cells became vulnerable again. The KRAS inhibitor regained its power.
Published in Cancer Cell, the findings propose a combination strategy: pair KRAS inhibitors with TBK1 blockade to shut down both the genetic escape routes and the tumor's adaptive inflammatory response. The work is still preclinical, but it offers a rational and concrete direction — one that frames resistance not as inevitable, but as a mechanism that can be anticipated and disrupted.
Nearly half of all colorectal cancers carry mutations in a gene called KRAS. For decades, this was a death sentence written in the genome—a marker of aggressive disease with few good options. Then came the inhibitors: adagrasib and sotorasib, drugs designed to shut down the faulty protein that KRAS produces. They worked, sort of. Some patients saw their tumors shrink. But the victories were brief. Within months, the cancer learned to fight back, and the drugs stopped working.
Researchers at UT MD Anderson Cancer Center and Weill Cornell Medicine wanted to understand why. What was happening inside these tumors when the drugs stopped working? The team, led by Salvador Alonso Martinez and Kevan Chu, collected tumor samples from patients before treatment began, while they were on KRAS inhibitors, and again when the cancer had progressed despite the drugs. They used advanced genetic sequencing and single-cell spatial transcriptomics—essentially mapping the behavior of individual cancer cells in their native tissue—to see what had changed.
What they found was more complicated than a simple mutation. Yes, some resistant cancer cells had acquired new genetic mutations that allowed them to bypass the drug's effects. But others hadn't mutated at all. Instead, they had changed their behavior. The cancer cells were shifting their identity, adopting new survival strategies without altering their DNA. Both mechanisms were often present in the same tumor, working in parallel.
The researchers discovered something else: when KRAS inhibitors first hit the tumor, they triggered what amounts to an alarm response in the cancer cells. The cells activated inflammatory pathways—essentially calling for help from their cellular neighborhood. This early inflammatory surge appeared to be the tumor's way of adapting, of buying time while it figured out how to resist the drug. It was a survival reflex, and it worked.
That observation pointed toward a solution. If the inflammatory response was helping the cancer survive, what if you blocked it? The team tested this in preclinical models—organoids grown from resistant tumors in the laboratory. When they added a drug that blocked TBK1, a protein central to that inflammatory cascade, the cancer cells became vulnerable again. The KRAS inhibitor could work once more.
The findings, published in Cancer Cell, suggest a new combination strategy: use KRAS inhibitors alongside TBK1 blockade. By shutting down both the cancer's genetic escape routes and its inflammatory survival response, the drugs might keep the upper hand longer. Alonso Martinez noted that the adapted inflammatory response may be the key to stopping resistance and improving outcomes for patients whose cancers currently exhaust these treatments within months.
For patients with KRAS-mutant colorectal cancer, the implications are significant but still preliminary. This is preclinical work—it has been tested in laboratory models and patient samples, not yet in living patients. But it offers a concrete direction for the next phase of research: a rational combination that targets not just the mutated gene, but the tumor's adaptive response to being attacked. The work suggests that resistance is not inevitable, that there may be a way to stay ahead of the cancer's ability to escape.
Citações Notáveis
Targeting the adapted early inflammatory response may be the key to stopping resistance and improving the effectiveness of KRAS therapies for these patients.— Salvador Alonso Martinez, MD, Assistant Professor of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center
A Conversa do Hearth Outra perspectiva sobre a história
Why does KRAS matter so much in colorectal cancer? Is it just because it's common?
It's common, yes—nearly half of cases—but that's not the whole story. KRAS controls a protein that tells cells to grow and divide. When it mutates, that signal gets stuck on. The cancer cells can't stop growing. For a long time, we had no way to turn that signal off.
And now we do, with these inhibitors. So why doesn't that solve the problem?
Because the tumor is smarter than we gave it credit for. When you hit it with a drug, it doesn't just sit there and die. It adapts. Some cells mutate in new ways to dodge the drug. Others change how they behave without changing their genes at all. Both are happening at once.
That sounds like the tumor is learning.
In a way, yes. It's not conscious learning, but it's adaptive. And the researchers found that when the drug first attacks, the tumor cells trigger an inflammatory response—like an immune alarm. That inflammation helps them survive long enough to figure out their escape route.
So blocking that inflammation could give the drug more time to work?
Exactly. If you block TBK1, which drives that inflammatory response, the cancer cells lose one of their survival tools. In the lab, when they combined TBK1 blockade with the KRAS inhibitor, the cancer stayed sensitive to the drug.
Is this ready for patients?
Not yet. This is preclinical work—proven in organoids and patient samples, but not in living people. But it's the kind of finding that points toward the next clinical trial. It's a rational strategy based on understanding how the tumor actually resists.
What happens if this works in patients?
It could extend the time these drugs remain effective. For patients with KRAS-mutant colorectal cancer, that could mean months or years of additional survival. Right now, the responses are short-lived. A combination that keeps the tumor from adapting would change the game.